Previous studies have shown that TGF-β1 levels are significantly increased in patients with adenomyosis, and anti-TGF-β1 treatment was found to reduce uterine collagen expression, thereby inhibiting fibrosis associated with adenomyosis. This evidence concerns the gene TGFB1 and adenomyosis.